WO2002053176A3 - An autologous anti-cancer vaccine - Google Patents

An autologous anti-cancer vaccine Download PDF

Info

Publication number
WO2002053176A3
WO2002053176A3 PCT/IL2002/000012 IL0200012W WO02053176A3 WO 2002053176 A3 WO2002053176 A3 WO 2002053176A3 IL 0200012 W IL0200012 W IL 0200012W WO 02053176 A3 WO02053176 A3 WO 02053176A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mixture
loaded
apc
antigen presenting
Prior art date
Application number
PCT/IL2002/000012
Other languages
French (fr)
Other versions
WO2002053176A2 (en
Inventor
Michal Lotem
Tamar Peretz
Eitan Shiloni
Olga Drize
Shoshana Frankenburg
Original Assignee
Hadasit Med Res Service
Michal Lotem
Tamar Peretz
Eitan Shiloni
Olga Drize
Shoshana Frankenburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Michal Lotem, Tamar Peretz, Eitan Shiloni, Olga Drize, Shoshana Frankenburg filed Critical Hadasit Med Res Service
Priority to AU2002219485A priority Critical patent/AU2002219485A1/en
Publication of WO2002053176A2 publication Critical patent/WO2002053176A2/en
Publication of WO2002053176A3 publication Critical patent/WO2002053176A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Abstract

The invention relates to a pharmaceutical composition for inducing an immune response directed against malignancies in a mammalian subject. The composition comprises as active ingredients autologous antigen presenting cell (APC) which were loaded with mixture of at least two allogenic tumor cell line lysates. Optionally, the composition of the invention may further comprise an IL-2 adjuvant. The invention further relates to a method for conferring immunity against a malignancy, in a mammalian subject in need, by administering an autologous antigen presenting cells (APC) loaded with a mixture of allogeneic cell lysates mixture, or a composition comprising the same to said subject. The invention further relates to the use of these loaded APC cells in the preparation of pharmaceutical composition for the treatment of malignant disorders, particularly, melanoma.
PCT/IL2002/000012 2001-01-08 2002-01-06 An autologous anti-cancer vaccine WO2002053176A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219485A AU2002219485A1 (en) 2001-01-08 2002-01-06 An autologous anti-cancer vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14079601A IL140796A0 (en) 2001-01-08 2001-01-08 An autologous anti-cancer vaccine
IL140796 2001-01-08

Publications (2)

Publication Number Publication Date
WO2002053176A2 WO2002053176A2 (en) 2002-07-11
WO2002053176A3 true WO2002053176A3 (en) 2002-12-19

Family

ID=11075015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000012 WO2002053176A2 (en) 2001-01-08 2002-01-06 An autologous anti-cancer vaccine

Country Status (3)

Country Link
AU (1) AU2002219485A1 (en)
IL (1) IL140796A0 (en)
WO (1) WO2002053176A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
EA200700598A1 (en) 2007-03-07 2007-12-28 Петр Генриевич ЛОХОВ ANTI-TUMOR VACCINE, METHOD FOR OBTAINING ANTI-TUMOR VACCINE AND METHOD FOR CARRYING OUT ANTITUMOR IMMUNOTHERAPY
AR060424A1 (en) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
CL2007002825A1 (en) 2007-09-28 2008-05-30 Univ De Chile Oncobiomed METHOD FOR GENERATING VACCINES THAT STIMULATE THE IMMUNE SYSTEM THAT INCLUDES INDUCTING PERIPHERAL BLOOD MONONUCLEAR CELLS TO BE DIFFERENTIATED FROM APC, THEN, SEPARATE SUCH APC AND MIX THEM WITH ADJUVANTS; EXTRACT OF TUMOR CELLS; AND COMP
WO2012156969A1 (en) * 2011-05-17 2012-11-22 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
KR20140143361A (en) * 2012-02-02 2014-12-16 캘리포니아 스템 셀, 인코포레이티드 Pluripotent germ layer origin antigen presenting cancer vaccine
CN103372203B (en) * 2012-04-17 2015-05-06 国家纳米科学中心 Antigen composition, preparation method and application of antigen composition and tumour vaccine
CN103800896A (en) * 2012-11-15 2014-05-21 厦门鹭佳生物科技有限公司 Preparation method and application of autologous tumor vaccine
CA2942610C (en) 2014-03-17 2024-02-20 Richard Kroczek Use of a medicament comprising a peptide-loaded peripheral blood mononuclear cell for extending a cellular cytotoxic immune response
WO2016201658A1 (en) * 2015-06-17 2016-12-22 深圳市达科为生物工程有限公司 Method for preparing tumor specific ctls

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033612A1 (en) * 1996-03-15 1997-09-18 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO2000040701A2 (en) * 1998-12-31 2000-07-13 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033612A1 (en) * 1996-03-15 1997-09-18 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO2000040701A2 (en) * 1998-12-31 2000-07-13 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAKRABORTY N. ET AL.: "Melanoma cell lysate loaded autologous antigen presenting cell (APC) as a vaccine in melanoma", PROC. AM. ASS. CANCER RES., vol. 38, pages 400, XP001080013 *
HERR W. ET AL.: "Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBY-specific CD4+ and CD8+ T lymphocyte responses", IMMUNOBIOLOGY, vol. 96, no. 5, 2000, pages 1857 - 1864, XP002203121 *
NESTLE F O ET AL: "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 3, March 1998 (1998-03-01), pages 328 - 332, XP002122868, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2002053176A2 (en) 2002-07-11
AU2002219485A1 (en) 2002-07-16
IL140796A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
MY129263A (en) Vaccine composition
MX2010001054A (en) Antigen-adjuvant compositions and methods.
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
HUP0101619A2 (en) Adjuvant compositions
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
MXPA03007837A (en) Compositions for delivering bisphosphonates.
IL155283A0 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
WO2006062807A3 (en) Compositions with enhanced immunogenicity
MXPA03007857A (en) Compounds and compositions for delivering active agents.
WO2002034119A3 (en) Vaccine immunotherapy for immune suppressed patients
WO2002053176A3 (en) An autologous anti-cancer vaccine
AU2003212170A1 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
WO2005067460A3 (en) Epha2 vaccines
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
AU2003260426A1 (en) Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
WO2003039592A3 (en) Cellular vaccines comprising adjuvants
WO2006114680A8 (en) Vaccine adjuvants
WO2003093298A3 (en) Immunogenic peptides
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
MY127452A (en) Vaccines.
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP